Scarica l'app Stockscreener
85.40
0.55%
0.47
Dopo l'orario di chiusura:
85.40
Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up - AOL.com
Kymera Therapeutics (KYMR) to present Phase 1b BroADen trial data for KT-621 at AAD 2026 - msn.com
Jeremy Chadwick Sells 7,600 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells $1,251,134.40 in Stock - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Director Sells $631,738.00 in Stock - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Director Elena Ridloff Sells 4,600 Shares - MarketBeat
Kymera Therapeutics COO sells $1.9 million in shares By Investing.com - Investing.com Canada
Kymera (KYMR) COO sells 22,240 shares after exercising options - Stock Titan
KYMR (NASDAQ) director/insider plans 4,600-share option exercise; prior 7,400-share 10b5-1 sale - Stock Titan
Form 144 and 10b5-1 sales reported for KYMR (NASDAQ: KYMR) - Stock Titan
Kymera's eczema drug gets fast track designation in the United States - msn.com
Layoff Watch: What are Kymera Therapeutics Incs earnings expectationsBear Alert & Free Verified High Yield Trade Plans - baoquankhu1.vn
[144] Kymera Therapeutics, Inc. SEC Filing - Stock Titan
Behavioral Patterns of KYMR and Institutional Flows - Stock Traders Daily
Aug Volume: Is Kymera Therapeutics Inc forming a bullish divergence2026 Geopolitical Influence & Fast Moving Stock Watchlists - baoquankhu1.vn
Does Positive KT-621 Atopic Dermatitis Data Change The Bull Case For Kymera Therapeutics (KYMR)? - Yahoo Finance
Kymera Therapeutics Updates Bylaws on Federal Securities Litigation - TipRanks
JPMorgan Chase & Co. Lowers Stock Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology Annual Meeting - Investing News Network
Kymera Therapeutics Reports Positive Phase 1b Results for KT-621 in Atopic Dermatitis at AAD Annual Meeting - Quiver Quantitative
Once-daily KT-621 cut dermatitis severity 63% in early trial - Stock Titan
Kymera Therapeutics, Inc. Amends Bylaws and Confirms Common Stock Registration on Nasdaq – SEC 8-K Filing March 2026 - Minichart
Aug PreEarnings: Can Kymera Therapeutics Inc weather a recessionWeekly Loss Report & Safe Entry Point Identification - baoquankhu1.vn
Kymera Therapeutics (KYMR) sets federal courts as exclusive forum for securities claims - stocktitan.net
Vanguard Group (NYSE: V) reports 0 KYMR shares after realignment - Stock Titan
Hedge Fund and Insider Trading News: Catherine Wood, Ray Dalio, Bill Ackman, Warren Buffett, Two Sigma Advisors, MGM Resorts International (MGM), Kymera Therapeutics Inc (KYMR), and More - Insider Monkey
VIX Spike: Will Kymera Therapeutics Inc be affected by tariffs2026 Reactions & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Kymera Therapeutics (NASDAQ:KYMR) COO Sells $7,063,662.50 in Stock - MarketBeat
Jeremy Chadwick Sells 24,727 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Kymera Therapeutics (KYMR) COO sells 115,977 shares after option exercise - stocktitan.net
Kymera Therapeutics (NASDAQ:KYMR) Shares Up 8.4%What's Next? - MarketBeat
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
KYMR (NASDAQ) insider 10b5-1 sales and option exercise reported - Stock Titan
Hudson Bay Capital Management LP Grows Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
A Look At Kymera Therapeutics (KYMR) Valuation After Late Breaking KT-621 AAD 2026 Selection - Sahm
Kymera’s KT-621 Faces "Sell the News" Risk as AAD Data and Dilution Collide - Bitget
Jobs Data: Can Kymera Therapeutics Inc benefit from deglobalization2026 Retail & Safe Entry Point Identification - baoquankhu1.vn
Kymera Q4 loss wider than expected, cash boost extends runway - MSN
Esposito sells Kymera (KYMR) shares worth $197,877 By Investing.com - Investing.com Canada
Kymera Therapeutics (KYMR) director exercises options, sells 2,500 shares under 10b5-1 plan - Stock Titan
KYMR (KYMR) Form 144 shows option exercise and 10b5-1 sales by insider - Stock Titan
Kymera Therapeutics (KYMR) to Present Phase 1b BroADen Trial Data for KT-621 at AAD 2026 - Insider Monkey
Stock Recap: Is Kymera Therapeutics Inc currently under institutional pressure2026 Closing Moves & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Highs Report: Is now the right time to enter Kymera Therapeutics IncMarket Performance Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
(KYMR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Nextech Invest Sells $4.19M in Kymera Shares, Stake Value Rises to $21.7MNews and Statistics - IndexBox
Nextech Trims Kymera at a Recent High — think Foolishly before acting. - AOL.com
Aug Selloffs: What is the long term forecast for Kymera Therapeutics Inc stock2026 Market Sentiment & Pattern Based Trade Signal System - baoquankhu1.vn
Aug Breakouts: What is Kymera Therapeutics Incs 5 year growth outlookPortfolio Return Report & Consistent Return Strategy Ideas - baoquankhu1.vn
Weekly Earnings: Is Kymera Therapeutics Inc currently under institutional pressure2026 Price Momentum & Smart Investment Allocation Insights - baoquankhu1.vn
HighVista Strategies LLC Makes New $890,000 Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):